DXS International (AQSE:DXSP) Research & Development: £0.00 Mil (TTM As of Apr. 2025)


What is DXS International Research & Development?

DXS International AQSE:DXSP Research & Development is £0.00 Mil as of Apr. 2025. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. DXS International's Research & Development for the six months ended in Apr. 2025 was £0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Apr. 2025 was £0.00 Mil.

DXS International  (AQSE:DXSP) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

DXS International Research & Development Related Terms

DXS International Research & Development Historical Data

* Premium members only.

The historical data trend for DXS International's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DXS International Research & Development Chart

DXS International Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

DXS International Semi-Annual Data
Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

DXS International Research & Development Calculation

This is the expense the company spent on research and development.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Research & Development for the trailing twelve months (TTM) ended in Apr. 2025 was £0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of £0.00 Mil mean?
DXS International (AQSE:DXSP) has a Research & Development of £0.00 Mil as of Apr. 2025. Research and development expense is the total cost for research and development activities. View historical data on DXS International and its competitors.
Is DXS International's Research & Development too high?
DXS International's current Research & Development is £0.00 Mil.
How does DXS International's Research & Development compare to VEEV and BTSG?
DXS International's Research & Development of £0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on DXS International and its competitors. DXS International's current Research & Development is £0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DXS International stock overvalued right now?
Based on GuruFocus' analysis, DXS International (AQSE:DXSP) is currently considered Possible Value Trap. The stock's GF Value™ is £0.02, compared to a current price of £0.01 — trading 37.5% below its estimated fair value. The current Research & Development is £0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For DXS International (AQSE:DXSP), the current Research & Development is £0.00 Mil as of Apr. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DXS International Business Description

Address 119 Saint Mary’s Road, Market Harborough, London, Leicestershire, GBR, LE16 7DT
DXS International PLC is engaged in the development and distribution of clinical decision support systems for General Practitioners, nurses, and retail pharmacies in the United Kingdom and South Africa. Its commercial activities include licensing DXS products to various ICBs, offering e-detailing opportunities to the pharmaceutical industry and the UK primary care sector, and licensing its technology to healthcare publishers. The company's products include BestPathway and Point-of-Care ExpertCare.